Director-Affiliated Entity Canaan VIII LP Files to Sell Another $13M in Liquidia Stock
LQDA has more than doubled off its 52-week low of $11.85.
Summary
Canaan VIII LP, a director-affiliated entity, has filed a Form 144 to sell an additional $13 million worth of Liquidia Corp common stock, continuing a pattern of significant insider distribution.
Key Events · Ownership and Investor Activity · LQDA
-
Proposed Stock Sale
Canaan VIII LP intends to sell 200,000 shares of Liquidia Corp common stock, valued at approximately $13 million.
-
Filer Identity
The selling entity, Canaan VIII LP, is affiliated with a director of Liquidia Corp.
-
Ongoing Distribution Pattern
This filing extends a recent trend of significant stock sales by Canaan VIII LP, which has sold over $43 million in the past three months through multiple Form 144 filings.
-
Market Context
The proposed sale occurs while Liquidia's stock is trading near its 52-week high, following recent positive news regarding Q1 earnings and S&P SmallCap 600 Index inclusion.
Analysis · LQDA · Life Sciences
This Form 144 indicates a significant intent to sell by Canaan VIII LP, an institutional investor with director affiliation. The $13 million proposed sale, representing a notable portion of the company's market capitalization, is substantial. This is part of a broader pattern of distribution by Canaan VIII LP, which has filed multiple Form 144s and sold over $43 million in the last three months. While Liquidia recently reported strong Q1 results and upcoming S&P SmallCap 600 inclusion, this continued insider selling by a major institutional holder could exert downward pressure on the stock, especially as it trades near its 52-week high.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LQDA was trading at $65.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $11.85 to $66.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.